Moderna Inc.
Moderna Reports 2024 Financial Results and Provides 2025 Outlook
Summary
Moderna, Inc. reported its financial results for the fourth quarter and full year of 2024, announcing a significant year-over-year decrease in revenues and an increase in net loss. For Q4 2024, the company reported revenues of $1.0 billion, GAAP net loss of $(1.1) billion, and GAAP EPS of $(2.91). Full-year 2024 revenues were $3.2 billion, with a GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28). Moderna also provided updates on its pipeline and financial outlook for 2025, anticipating a revenue range of $1.5 to $2.5 billion and an ending cash balance of approximately $6 billion.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement